Amansa Investments is pumping RS 250 CR in Rubicon Research in pre-Ipho Financing Round; Problem at the end of the year

Amansa Investments LTD has invested RS 250 Crore in pharmaceutical formulation company Rubicon Research LTD via a pre-initial public sacrifice (IPO) financing round.

Rubicon Research is expected to be released by the end of this year’s first public issue, according to people who are familiar with the case.

As part of the transaction, General Atlantic Singapore RR PTE LTD, one of the promoters of Rubicon Research, transferred 51.60 shares from Lakh to Amansa Investments on RS 484.47 per share, which is intended for RS 250 Crore, the company said on Thursday in a public announcement on a public announcement.

At the time of submitting design papers in July 2024, General Atlantic had 8.89 shares of Crore shares, with an interest of 57.34 percent. After the pre-ipo deal it will have 8.37 crore shares, or 54.01 percent of the company.

The transaction, carried out in consultation with the book Running Lead Managers (BRLMS) from Rubicon Research, received the approval of the Council on 12 August on 12 August.

Other promoters of the company are Pratibha Pilgaonkar, Sudhir D Pilgaonkar, Parag S Sancheti, Surabhi P Sancheti and Sumant S Pilgaonkar. The proposed IPO from Rubicon Research consisted of a new edition of shares of RS 500 Crore in addition to an offer for sale of shares with a value of RS 585 Crore. After the last fundraising, the size of the new problem would be reduced. The company intends to use the proceeds of the new issue for the payment of debts, in support of inorganic growth by non -created acquisitions, as well as other strategic initiatives and general business purposes. In June, Rubicon Research completed the acquisition of the production facility of Alkem Laboratories in Pithampur, Madhya Pradesh in an All-cash deal for RS 149 Crore.

Rubicon Research is a company for pharmaceutical formulations, driven through innovation through targeted research and development, with an increasing portfolio of specialist products and combination products from drug devices aimed at regulated markets and in particular the United States.

The pharmaceutical company has two American FDA-inspired research and development facilities (R&D), one in India and Canada, and two production facilities in India with multiple accreditations of multiple regulatory authorities such as USFDA, Food and Drugs Administration, Maharashtra (WHOMP accidention).

On March 31, 2024, the company had approved a portfolio of 69 products by the USFDA, 19 new medicines pending the Knik van USFDA and 46 products in different stages of development.